Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Seeks partnership between government and private medical colleges for providing superior medical education
Acquisitions have the potential to add at least $1 billion in sales by 2028
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The company is one of the most profitable companies manufacturing speciality chemicals in India
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
Subscribe To Our Newsletter & Stay Updated